AUTHORS
Rahul Banerjee, MD, Yair Levy, MD2, Beth Faiman, PhD, MSN, APN-BC, AOCN®, TCTCN®, FAAN, FAPO3, Jonathan L Kaufman, MD4, Samer Al Hadidi, MD5, Carlyn Rose Tan, MD6, Karim Iskander7, Joseph Mikhael, MD, MEd8
AFFILIATIONS
1 Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Hematologic Malignancies Research, Baylor University Medical Center, Dallas, Texas, United States
3 Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, United States
4 Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, United States
5 Division of Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Sanofi, Cambridge, Massachusetts, United States
8 Division of Clinical Genomics and Therapeutics, Translational Genomics Research Institute, Phoenix, Arizona, United States
ABSTRACT
Introduction: CD38-directed monoclonal antibodies are a cornerstone for the treatment of multiple myeloma but can be associated with systemic infusion-related reactions (IRRs). Higher-grade IRRs pose a safety risk for patients, while lower-grade IRRs impact logistical considerations and patient time/experience in clinic. Subcutaneous (SC) formulations have lessened but have not eliminated the risk of IRRs. To better understand differences between isatuximab and daratumumab formulations and methods of administration, we conducted a systematic review of safety outcomes from the clinical trial programs and quantified IRR risk with intravenous (IV) and SC routes of administration for both drugs. We also sought to determine if the inclusion of montelukast premedication resulted in lower IRR risk.
Methods: A PubMed literature search was conducted on April 30, 2026, with no date limits. Original clinical trial reports were included if they contained data on IRRs. Dose-finding studies were excluded, as were trials with ≤10 patients. Supplementary data and protocols were reviewed for premedication protocols to determine montelukast use and inclusion/exclusion criteria with a focus on comorbidities such as asthma/chronic obstructive pulmonary disease (COPD). The percentage of patients with systemic IRRs was obtained for isatuximab IV and daratumumab IV, isatuximab SC manual and daratumumab SC manual and isatuximab SC on-body injector (OBI) administration by dividing the number of patients with ≥ 1 IRR event by the total number of patients in the trials. Data were summarized using descriptive statistics.
Results: Inclusion/exclusion criteria were broadly similar across clinical programs, with the notable exception that most daratumumab trials excluded patients with moderate-to-severe asthma in the last 2 years or uncontrolled asthma and/or COPD with a forced expiratory volume in 1 second (FEV1) of <50% or 60% of predicted normal. In the IV and SC daratumumab trials, 34/36 (94%) studies excluded COPD or asthma or both. In isatuximab trials, 1/14 (7%) excluded patients with asthma and/or COPD.
Data on IRR incidence were included from 12 clinical trials with IV isatuximab (N=1354), 28 clinical trials with IV daratumumab (N=4093), 4 clinical trials with SC isatuximab (manual or OBI) (N=443), and 9 clinical trials with SC daratumumab (N=1549). Some trials included more than one route of administration. Overall percentages of patients with IRRs were 29.7% (range: 8%-46%) with IV isatuximab and 38.4% (range: 4%-55%) with IV daratumumab. Grade ≥3 IRR percentages were 1.1% and 4.8%, respectively. In isatuximab SC trials, 60 patients received manual SC administration and had an IRR percentage of 5.0% (range 4%-10%). In the daratumumab SC trials, 1549 patients received manual SC administration and the overall percentage of patients with IRRs was 9.4% (range: 4%-21%). Across the 4 trials of isatuximab SC, 383 patients received the SC OBI administration, and the overall percentage of IRRs in this group was 2.1% (range: 0%-5%). Percentages of grade ≥3 IRRs in the SC groups were <0.5% with isatuximab SC (manual and OBI) and 1% with daratumumab SC.
Montelukast was mandatory or optional as premedication in approximately half of IV trials and in all SC trials in which the protocol was available. Within protocols where montelukast was included as a premedication for the first dose, percentages of patients with IRRs were 22.9% for IV isatuximab and 35.5% for IV daratumumab.
Conclusions: Isatuximab administered SC via OBI was associated with the lowest IRR risk (2.1%) among CD38-directed monoclonal antibodies. Risk difference is likely due to the unique mechanism of the OBI. Inclusion of montelukast as premedication before the first dose was associated with a lower percentage of patients with IRR regardless of agent and should be adopted uniformly for initiation of anti-CD38 therapy in trials and real-world practice.
DISCLOSURES
Rahul Banerjee, MD: BMS - Research Funding; Sanofi - Research Funding; Abbvie - Research Funding; Prothena - Research Funding; Johnson & Johnson - Research Funding; Pack Health - Research Funding; Novartis - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); SparkCures - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Poseida Therapeutics - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Adaptive Biotech - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Gilead/Kite - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)